Insulin-like growth factor I gene expression by primary cultures of ovarian cells: insulin and dexamethasone dependence

Molecular crosstalk between insulin-like growth factors and follicle-stimulating hormone in the regulation of granulosa cell function

Background

The last phase of folliculogenesis is driven by follicle-stimulating hormone (FSH) and locally produced insulin-like growth factors (IGFs), both essential for forming preovulatory follicles.

Methods

This review discusses the molecular crosstalk of the FSH and IGF signaling pathways in regulating follicular granulosa cells (GCs) during the antral-to-preovulatory phase.

Main findings

IGFs were considered co-gonadotropins since they amplify FSH actions in GCs. However, this view is not compatible with data showing that FSH requires IGFs to stimulate GCs, that FSH renders GCs sensitive to IGFs, and that FSH signaling interacts with factors downstream of AKT to stimulate GCs. New evidence suggests that FSH and IGF signaling pathways intersect at several levels to regulate gene expression and GC function.

Conclusion

FSH and locally produced IGFs form a positive feedback loop essential for preovulatory follicle formation in all species. Understanding the mechanisms by which FSH and IGFs interact to control GC function will help design new interventions to optimize follicle maturation, perfect treatment of ovulatory defects, improve in vitro fertilization, and develop new contraceptive approaches.

Glucocorticoid suppression of intraovarian levels of prostaglandins and plasminogen activator activity at ovulation in the rat ovary

AIM

Ovulation is a local physiological inflammatory process with active participation of inflammatory mediators and immune cells. To prevent extensive inflammatory injury to the follicle at ovulation there is also a local anti-inflammatory system at ovulation, converting the inactive glucocorticoid cortisone to the more potent cortisol. The aim of this study was to examine the effects of the potent glucocorticoid analogue, dexamethasone (DEX), on ovulation rate and the ovarian production of the ovulatory mediators prostaglandins (PG) and plasminogen activators (PA).

METHODS

DEX (0.3, 3, or 100 microM) was administered to an in vitro rat ovarian perfusion system prior to the addition of an ovulation-inducing dose of luteinizing hormone (LH) and 3-isobutyl-1-methylxanthine (IBMX). Control ovaries were perfused only with LH + IBMX. Each perfusion experiment extended over 20 h with ovulation occurring in vitro around 12-15 h after hormonal stimulation. In a second set of perfusion experiments, extending over 10 h, the tissue levels of PG and PA activity in the ovary were evaluated at a time 2-5 h before anticipated ovulation.

RESULTS

The median numbers of ovulated oocytes in the groups with DEX of 0.3, 3, and 100 microM were 17.0, 8.5 and 11.0 per treated ovary, respectively. These numbers were not different from those of LH + IBMX-controls (12.5). DEX (100 microM) suppressed tissue levels of PGE(2) and PA activity and decreased (DEX 3 microM, 100 microM) estradiol levels in the perfusion media.

CONCLUSION

These results indicate that certain degrees of suppression of PG, PA activity, and estradiol are not sufficient to modulate ovulation rate and/or that glucocorticoids may positively modulate other mediator pathways that exert inhibitory influence on ovulation.

The effect of dexamethasone on disruption of ovarian steroid levels and receptors in female rats

This study was conducted to investigate if the injection of a single dose of dexamethasone may cause disruption of adult female rat gonadal function in terms of plasma and ovarian level of both androgen and estrogen, ovarian morphology, and changes in localization of androgen, estrogen and glucocorticoid receptors. Adult female Long Evans rats (n=50, 250-300 g) were used. At day 0 rats received subcutaneously 1 ml of saline (n=25; control group) or dexamethasone at 0.1 mg/kg (n=25, treated group). Rats were sacrificed in groups of five on days 10, 15, 20, 25 and 30 after injection. Blood samples and one ovary were collected to analyze dexamethasone, 17beta-estradiol (E2), testosterone (T) and androstenedione (A4) concentrations by amplified EIA. The remaining ovary was removed and processed for histopathology and immunocytochemistry. Differences between individual means were analyzed by Pairwise t-test and Bonferroni post test to asses whether values presented statistical significance. Increased E2, T and A4 levels were observed both in plasma and ovary samples in treated group when comparing with control (p< 0.01) at all days post-injection even when dexamethasone was undetectable. Ovarian morphology of treated group showed features compatible with female infertility. Inmmunolocalization of androgen and estrogen receptors showed that both were negative in treated group while controls showed highest positivity (AR +++, ER ++). Glucocorticoid receptor showed higher positivity in dexamethasone treated rats (GR ++) than in controls (GR +). Obtained results showed clear evidence that a single dose of dexamethasone may disrupt gonadal function in rats, and that possibly leads to infertility.

Effects of growth hormone, activin, and follistatin on the development of preantral follicle from immature female mice

The aim of this study was to investigate whether GH and insulin-like growth factor I (IGF-I) are involved in preantral folliculogenesis and, if so, to clarify the relationship between GH/IGF-I and activin/follistatin (FS) systems in immature female mice. Ovaries were obtained from 11-day-old mice, and preantral follicles, 100-105 microm in diameter, were mechanically isolated and selected for culture. Ten preantral follicles per well were cultured with different quantities and combinations of additives as follows: no additives (control), recombinant human FSH (rhFSH), IGF-I, recombinant human GH (rhGH), activin A, and recombinant human FS (rhFS). Mean diameters of the follicles were measured daily, and estradiol and immunoreactive inhibin levels in the cultured medium were assayed by RIA on day 4. rhGH showed stimulatory effects on the follicular diameter and the secretion of estradiol and immunoreactive inhibin. These effects were augmented by the presence of IGF-I and activin A. IGF-I alone did not show any stimulatory effect. The addition of rhFSH to activin A or to rhGH and activin A promoted preantral follicular growth and hormone production. On the other hand, GH- or activin-stimulated follicular growth was suppressed by rhFS in a dose-dependent manner. These results indicate that activin A and rhGH may play an important role in controlling earlier phases of follicular development during the infantile period, which is considered to be gonadotropin independent.

Insulin-like growth factor I regulates gonadotropin responsiveness in the murine ovary

The present study shows that insulin-like growth factor I (IGF-I) and FSH receptor (FSHR) mRNAs are selectively coexpressed in a subset of healthy-appearing follicles in murine ovaries, irrespective of cycle stage. Aromatase gene expression, a prime marker for FSH effect, is found only in IGF-I/FSHR-positive follicles, showing that these are healthy, gonadotropin-responsive follicles. Given the striking coexpression of FSHR and IGF-I, we hypothesized that FSH was responsible for follicular IGF-I expression. We found, however, that granulosa cell IGF-I mRNA levels are not reduced in hypophysectomized (+/-PMSG) or FSH knockout mice, indicating that FSH does not have a major role in regulation of granulosa cell IGF-I gene expression. To test the alternative hypothesis that IGF-I regulates FSHR gene expression, we studied ovaries from IGF-I knockout mice. FSHR mRNA was significantly reduced in ovaries from homozygous IGF-I knockout compared with wild type mice and was restored to control values by exogenous IGF-I treatment. The functional significance of the reduced FSHR gene expression in IGF-I knockout ovaries is suggested by reduced aromatase expression and by the failure of their follicles to develop normally beyond the early antral stage. In fact, IGF-I knockout and FSH knockout ovaries appear very similar in terms of arrested follicular development. In summary, we have shown that IGF-I and FSHR are selectively coexpressed in healthy, growing murine follicles and that FSH does not affect IGF-I expression but that IGF-I augments granulosa cell FSHR expression. These data suggest that ovarian IGF-I expression serves to enhance granulosa cell FSH responsiveness by augmenting FSHR expression.

The mouse intraovarian insulin-like growth factor I system: departures from the rat paradigm

Although the rat intraovarian insulin-like growth factor I (IGF-I) system is well documented, the increasing availability of null mouse mutants for components of the IGF system necessitates characterization of the mouse model as well. Therefore, we undertook to define the components of the mouse intraovarian IGF-I system and to examine its operational characteristics. The cellular pattern of ovarian gene expression was comparable in the immature rat and mouse for IGF-I and the type I IGF receptor. In both species, IGF-I messenger RNA (mRNA) is selectively expressed by granulosa cells in growing, healthy appearing follicles. Type I IGF receptor mRNA was also concentrated in granulosa cells, but was uniformly expressed in all follicles large and small, healthy and atretic appearing alike. Cellular patterns of IGF-binding protein (IGFBP) gene expression were similar in mouse and rat, except in the case of IGFBP-2. IGFBP-2 mRNA was localized to the mouse granulosa cell, in contrast to its concentration in the rat thecal-interstitial compartment. This difference in IGFBP expression pattern was also noted in cultured mouse and rat granulosa cells. Although immunoreactive IGFBP-4 (24 and 28 kDa) and IGFBP-5 (29 kDa) were shared by both species, the cultured mouse granulosa cell also featured immunoreactive IGFBP-2 (30 kDa). The mouse paradigm further differed from its rat counterpart in that a maximal dose of FSH, previously shown to suppress the elaboration of rat granulosa cell-derived IGFBPs, was without effect. The addition of IGF-I proved stimulatory to the accumulation of the 28- to 29-kDa IGFBPs, as previously reported for the rat. However, IGF-I proved inhibitory to the accumulation of the 24-kDa IGFBP (presumptive nonglycosylated IGFBP-4); no consistent effect was reported for the rat model. Functional comparisons of mouse and rat ovarian cell cultures revealed qualitatively comparable FSH-stimulated steroidogenesis, disposition of radiolabeled pregnenolone, IGF-I-amplified FSH action, and IGFBP-mediated antigonadotropic activity. These findings indicate that the mouse intrafollicular IGF-I system differs from the rat paradigm in both the makeup and regulation of granulosa cell-derived IGFBPs as well as in the intensity and character of the steroidogenic process. Studies employing the mouse model must take into account these important distinctions relative to the more established rat paradigm.

Insulin-like growth factor-I (IGF-I) colocalizes with IGF-binding proteins (IGFBPs) in mouse and rat ovary

The cellular localization of insulin-like growth factor (IGF)-I mRNA, IGF-I peptide, and IGF-binding proteins (IGFBPs) was examined in mouse and rat ovaries through use ofin situ hybridization and immunohistochemical methods. IGF-I mRNA was found to be most abundant in granulosa cells, although lower levels were also detected in cells of the theca interna, stroma, and corpus luteum. In contrast, IGF-I immunoreactivity was undetectable or low in granulosa cells, weak and variable in oocytes, high in theca interna and the corpus luteum, and highest in the stroma. Antibodies directed against IGFBP-2, 3, and 5 yielded similar patterns of immunoreactivity to that observed for IGF-I peptide. The results indicate that IGF-I is synthesized in ovarian follicles, and that IGF-I of ovarian or systemic origin becomes localized to sites containing IGFBPs in the ovary.

Ovarian control of follicle development

A variety of ovarian autocrine and paracrine factors may modulate folliculogenesis and steroid production. The developmental program that leads to the production of a dominant follicle involves a precise quantitative and temporal pattern of expression of a large number of genes. Follicle-stimulating hormone plays an essential role in this process, and no other ligand by itself can serve in this regulatory capacity. It is clear that a variety of growth factors can modulate follicle-stimulating hormone action by autocrine and paracrine mechanisms. Advances in the understanding of the role of growth factors, particularly the family of insulin-like growth factor-related proteins, in regulating follicle-stimulating hormone action are discussed. It is likely that complex interactions exist between follicle-stimulating hormone and the growth factors. Significantly, growth factor regulation by pituitary gonadotropins is probably a central feature of their expression. With increased understanding of the ovarian control of follicle development, it is hoped that newer and more effective regimens for synchronous follicular and oocyte maturation can be realized.

Dexamethasone potentiates IGF-I actions in porcine granulosa cells

To understand better interactions between glucocorticoids and insulin-like growth factor I (IGF-I) in the ovary, we studied the effects of dexamethasone on IGF-I stimulation of P-450 cholesterol side-chain cleavage enzyme (P-450scc) mRNA concentrations in porcine granulosa cells. Dexamethasone potentiated IGF-I-stimulated P-450scc mRNA concentrations and progesterone production in granulosa cell cultures. Time-course and dose-response studies showed that maximal enhancement occurred at a 1-microM dexamethasone concentration after 48 h of treatment. This potentiation was prevented by the glucocorticoid receptor antagonist RU-38486, 17 beta-hydroxy-11 beta-[-4-dimethyl-aminophenyl]estra-4,9,-dien-3-one (RU-486). We investigated mechanisms for this potentiation by performing IGF-I binding studies in porcine granulosa cells. Dexamethasone increased IGF-I binding, and Scatchard analysis showed this enhanced binding was caused by an increase in receptor concentration. Northern blot hybridization using a rat type I IGF-I receptor gene riboprobe showed that although dexamethasone alone did not increase IGF-I receptor mRNA concentrations, it did prevent a decrease in receptor mRNA concentrations caused by IGF-I. In addition, we used synthetic primers from conserved regions of the rat type I IGF-I receptor gene with total RNA from porcine granulosa cells and polymerase chain reaction to isolate a 615-base pair porcine type I IGF-I receptor cDNA clone. Ribonuclease protection assay results were similar to those found with the rat IGF-I receptor riboprobe. We conclude that dexamethasone potentiates IGF-I actions on steroidogenesis in the porcine ovary.